PMID- 27821509
OWN - NLM
STAT- MEDLINE
DCOM- 20170823
LR  - 20220330
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 129
IP  - 3
DP  - 2017 Jan 19
TI  - Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC 
      and BCL2 and/or BCL6 rearrangements.
PG  - 280-288
LID - 10.1182/blood-2016-02-636316 [doi]
AB  - High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements, 
      so-called "double-hit" lymphomas (HGBL-DH), are aggressive lymphomas that form a 
      separate provisional entity in the 2016 revised World Health Organization 
      Classification of Lymphoid Tumors. Fluorescence in situ hybridization (FISH) will 
      be required to identify HGBL-DH and will reclassify a subset of diffuse large 
      B-cell lymphomas (DLBCLs) and HGBLs with features intermediate between DLBCL and 
      Burkitt lymphoma into this new category. Identifying patients with HGBL-DH is 
      important because it may change clinical management. This poses a challenge for 
      centers that may not be ready to handle the additional workload and financial 
      burden associated with the increase in requests for FISH testing. Herein, we 
      review the mechanisms of deregulation of these oncogenes. We identify the factors 
      associated with a poor prognosis and those that can guide diagnostic testing. 
      Restricting FISH analysis to the 10% of DLBCL patients who have a germinal center 
      B-cell phenotype and coexpress MYC and BCL2 proteins would be cost-effective and 
      would identify the subset of patients who are at highest risk of experiencing a 
      relapse following conventional therapy. These patients may benefit from 
      intensified chemotherapy regimens or, ideally, should enroll in clinical trials 
      investigating novel regimens.
CI  - (c) 2017 by The American Society of Hematology.
FAU - Sesques, Pierre
AU  - Sesques P
AD  - Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada; and.
FAU - Johnson, Nathalie A
AU  - Johnson NA
AUID- ORCID: 0000-0002-3211-9722
AD  - Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada; and.
AD  - Departments of Medicine and Oncology, McGill University, Montreal, QC, Canada.
LA  - eng
GR  - 299607/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20161107
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, B-Cell/*classification/diagnosis/genetics/therapy
MH  - Oncogenes/*genetics
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - Proto-Oncogene Proteins c-bcl-6/genetics
MH  - Proto-Oncogene Proteins c-myc/genetics
EDAT- 2016/11/09 06:00
MHDA- 2017/08/24 06:00
CRDT- 2016/11/09 06:00
PHST- 2016/02/03 00:00 [received]
PHST- 2016/10/25 00:00 [accepted]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/08/24 06:00 [medline]
PHST- 2016/11/09 06:00 [entrez]
AID - S0006-4971(20)33770-8 [pii]
AID - 10.1182/blood-2016-02-636316 [doi]
PST - ppublish
SO  - Blood. 2017 Jan 19;129(3):280-288. doi: 10.1182/blood-2016-02-636316. Epub 2016 
      Nov 7.